Resources

This application note provides an overview of the creation of breast and prostate multicellular tumour spheroids using RASTRUM™.

This application note provides an overview of the creation of direct co-culture models using RASTRUM™.

This application note demonstrates how cells encapsulated in RASTRUM™ Matrices can be easily retrieved to enable investigations into gene and protein expression.

This application note demonstrates the compatibility of imaging methods with 3D cell models created using RASTRUM™.

This application note provides an overview of the utility and tunability of RASTRUM™ matrix systems.

This application note details the key printing features offered by RASTRUM™.

This protocol outlines how the enzymatic-based RASTRUM™ Cell Recovery Solution can be used to extract 3D cell models encapsulated in RASTRUM™ Matrices for use in downstream applications.

This protocol outlines a method to assess viability of 3D Cell Models created with RASTRUM™ using fluorescent dyes for distinguishing live and dead cells via fluorescence microscopy.

This protocol outlines a method to analyse protein expression via immunofluorescence in 3D cell models created with RASTRUM™.

Chen, X.; O’Mahony, A.P. and Barber, T. The characterization of particle number and distribution inside in-flight 3D printed droplets using a high speed droplet imaging system. J. Appl. Phys. 2021, 130, 044701; https://doi.org/10.1063/5.0058817

Abstract

3D bioprinting is an innovative and time-saving method to precisely generate cell-laden 3D structures for clinical and research applications. Ejected cell number and cell distribution are two key technical parameters for evaluation of the bioprinter performance. In this paper, a modified droplet imaging system is used to study cell-size fluorescent particle number and distribution within droplets ejected from a microvalve-based 3D bioprinter. The effects of droplet dispensing physics (dosing energy 𝐸𝑑Ed), ink properties (Z number—the inverse of the Ohnesorge number and particle sedimentation velocity), and input particle concentration are considered. The droplet imaging system demonstrates a strong capability in analyzing bioprinting performance for seeded concentrations less than 3×1063×106 particles/ml. The printed particle number increases near-linearly under increasing dosing energy and Z number. It was found that for 7<Z<217<Z<21 and seeded particle concentration no less than 3×1063×106 particles/ml, particles within the visualized droplets approached a homogeneous distribution in the 2D images. It was also determined that the particle sedimentation velocity within the ink has a positive relationship to the ejected particle number over time—with the particle distribution approaching a homogeneous state over increasing sedimentation time.

Belfiore, L.; Aghaei, B.; Law, A.M.K.; Dobrowolski, J.C.; Raftery, L.J.; Tjandra, A.D.; Yee, C.; Piloni, A.; Volkerling, A.; Ferris, C.J. and Engel, M. Generation and Analysis of 3D Cell Culture Models for Drug Discovery (Review). Eur. J. Pharm. Sci. 2021, 105876; https://doi.org/10.1016/j.ejps.2021.105876

Abstract

Successful preclinical drug testing relies in part on data generated using in vitro cell culture models that recapitulate the structure and function of tumours and other tissues in vivo. The growing evidence that 3D cell models can more accurately predict the efficacy of drug responses compared to traditionally utilised 2D cell culture systems has led to continuous scientific and technological advances that enable better physiologically representative in vitro modelling of in vivo tissues. This review will provide an overview of the utility of current 3D cell models from a drug screening perspective and explore the future of 3D cell models for drug discovery applications.

Mahmodi, H., Piloni, A.; Utama, R. and Kabakova, I. Mechanical Mapping of Bioprinted Hydrogel Models by Brillouin Microscopy. Bioprinting. 2021. e00151; https://doi.org/10.1016/j.bprint.2021.e00151

Abstract

Three-dimensional (3D) bioprinting has revolutionised the field of biofabrication by delivering precise, cost-effective and a relatively simple way of engineeringin vitroliving systems in high volume for use in tissue regeneration, biological modelling, drug testing and cell-based diagnostics. The complexity of modern bioprinted systems requires quality control assessment to ensure the resulting product meets the desired criteria of structural design, micromechanical performance and long-term durability. Brillouin microscopy could be an excellent solution for micromechanical assessment of the bioprinted models during or post-fabrication since this technology is non-destructive, label-free and is capable of microscale 3D imaging. In this work, we demonstrate the application of Brillouin microscopy to 3D imaging of hydrogel microstructures created through drop-on-demand bioprinting. In addition, we show that this technology can resolve variations between mechanical properties of the gels with slightly different polymer fractions. This work confirms that Brillouin microscopy can be seen as a characterisation technology complementary to bioprinting, and in the future can be combined within the printer design to achieve simultaneous real-time fabrication and micromechanical characterisation ofin vitrobiological systems.

Orcheston-Findlay, L.; Bax, S.; Utama, R.; Engel, M.; Govender, D. and O’Neill, G. Advanced Spheroid, Tumouroid and 3D Bioprinted In-Vitro Models of Adult and Paediatric Glioblastoma (Review). Int. J. Mol. Sci. 2021, 22(6), 2962; https://doi.org/10.3390/ijms22062962

Abstract

The life expectancy of patients with high-grade glioma (HGG) has not improved in decades. One of the crucial tools to enable future improvement is advanced models that faithfully recapitulate the tumour microenvironment; they can be used for high-throughput screening that in future may enable accurate personalised drug screens. Currently, advanced models are crucial for identifying and understanding potential new targets, assessing new chemotherapeutic compounds or other treatment modalities. Recently, various methodologies have come into use that have allowed the validation of complex models—namely, spheroids, tumouroids, hydrogel-embedded cultures (matrix-supported) and advanced bioengineered cultures assembled with bioprinting and microfluidics. This review is designed to present the state of advanced models of HGG, whilst focusing as much as is possible on the paediatric form of the disease. The reality remains, however, that paediatric HGG (pHGG) models are years behind those of adult HGG. Our goal is to bring this to light in the hope that pGBM models can be improved upon.

Engel, M.; Belfiore, L.; Aghaei, B. and Sutija, M. Enabling High Throughput Target-Based Drug Discovery in 3D Cell Cultures Through Novel Bioprinting Workflow. bioRxiv. 2021; https://doi.org/10.1101/2021.04.21.440768

Abstract

Advanced three-dimensional cell culture techniques have been adopted in many laboratories to better model in vivo tissue by recapitulating multi-cellular architecture and the presence of extracellular matrix features. We describe here a 3D cell culture platform in a small molecule screening workflow that uses traditional biomarker and intracellular kinase end point assay readouts. By combining the high throughput bioprinter Rastrum with the high throughput screening assay AlphaLISA, we demonstrate the utility of the workflow in 3D synthetic hydrogel cultures with breast cancer (MDA-MB-231 and MCF-7) and fibroblast cells. To establish and validate the workflow, we treated the breast cancer cultures with doxorubicin, while fibroblast cultures were stimulated with the pro-inflammatory lipopolysaccharide. 3D and 2D MDA-MB-231 cultures were equally susceptible to doxorubicin treatment, while showing opposite ERK phosphorylation changes. Doxorubicin readily entered embedded MCF-7 spheroids and markedly reduced intracellular GSK3β phosphorylation. Furthermore, quantifying extracellular interleukin 6 levels showed a very similar activation profile for fibroblasts in 2D and 3D cultures, with 3D fibroblast networks being more resistant against the immune challenge. Through these validation experiments we demonstrate the full compatibility of the bioprinted 3D cell cultures with several widely-used 2D culture assays. The efficiency of the workflow, minimal culture handling, and applicability of traditional screening assays, demonstrates that advanced encapsulated 3D cell cultures can be used in 2D cell culture screening workflows, while providing a more holistic view on cell biology to increase the predictability to in vivo drug response.

Utama, R. H.; Atapattu, L.; 1 3, O'Mahony, A. P.; Fife, C. M.; Baek, J.; Allard, T.; O'Mahony, K. J.; Ribeiro, J. C. C.; Gaus, K.; Kavallaris, M. and Gooding, J. J. A 3D Bioprinter Specifically Designed for the High Throughput Production of Matrix-Embedded Multicellular Spheroids. iScience. 2020, 23(10):101621; https://doi.org/10.1016/j.isci.2020.101621

Abstract

3D in vitro cancer models are important therapeutic and biological discovery tools, yet formation of matrix-embedded multicellular spheroids in a throughput and highly controlled manner to achieve robust and statistically relevant data, remains challenging. Here, we developed an enabling technology consisting of a bespoke drop-on-demand 3D bioprinter capable of high-throughput printing of 96-well plates of spheroids. 3D-multicellular spheroids are embedded inside a tissue-like matrix with precise control over size and cell number. Application of 3D bioprinting for high-throughput drug screening was demonstrated with doxorubicin. Measurements showed that IC50 values were sensitive to spheroid size, embedding and how spheroids conform to the embedding, revealing parameters shaping biological responses in these models. Our study demonstrates the potential of 3D bioprinting in a tuneable and biologically relevant environment as a robust high-throughput platform to screen biological and therapeutic parameters.

Read our Press Release here.
Company aims to democratise access to affordable biomedical research especially in cancer research and new drug development through its novel 3D cell culture platform

Read our Press Release here.
As a result of this partnership, Inventia Life Science will now offer BioLamina’s extensive range of Biolaminin® products incorporated into the pre-validated library of RASTRUM™ Matrices, recapitulating the key motifs found in the native tissue of various cell types.

Read the article by the 3D Printing Media Network here.

The prestigious Good Design Award of the Year was awarded to the revolutionary RASTRUM™ 3D Bioprinter that is helping to fight cancer by building 3D cell structures which are then used to test a range of therapies.

Read the article by Fast Company here.

Inventia Life Sciences' RASTRUM™—a winner of Fast Company’s 2020 World Changing Ideas Awards—uses the technology of an inkjet printer to create lifelike human cell structures so biologists can see how drugs work on real cells.

Read the article by PRWeb here.

RASTRUM™ has taken out the top prize in the Experimental category. RASTRUM™ prints human cells into living tissue models to supercharge research into cancer and other diseases using revolutionary drop-on-demand technology.

Read the article by 3DPrint.com here.

Sydney based start-up company, Inventia Life Science has developed digital bioprinting technology for fast, scalable, and reproducible printing of 3D cell models.

Read the article by the Centre of Oncology Education and Research Translation (CONCERT) here.

When Associate Professor Kieran Scott goes to sleep at night, he dreams of fighting cancer… and winning. When he awakens, he goes to work, excited to be working on projects which are bringing his dreams closer to reality.

This short video interview with Dr Julio Ribeiro, co-founder and CEO of Inventia Life Science, speaks about RASTRUM being honoured by Fast Company in the 2020 World Changing Ideas Awards in the Experimental Category.

This podcast featured in Mark Bouris’ ‘The Mentor’ series will take you on the Inventia Life Science journey - from initial idea to the internationally acclaimed RASTRUM™ 3D Cell Culture Platform.
**Podcast may not be accessible outside Australia**

Click here to download the Frequently Asked Questions related to the RASTRUM™ Cell Culture Platform.

Click here to download the Frequently Asked Questions related to RASTRUM™ Hydrogels.

Click here to download the Frequently Asked Questions related to RASTRUM™ Applications.

Click here to download the Frequently Asked Questions related to RASTRUM™ Laboratory Requirements.

• Heinrich, M.A.; Liu, W.; Jimenez, A.; Yang, J.; Akpek, A.; Liu, X.; Pi, Q.; Mu, X.; Hu, N.; Schiffelers, R.M.; Prakash, J.; Xie, J. and Zhang, Y.S. 3D Bioprinting: from Benches to Translational Applications. Small. 2019, 15(23):e1805510; https://doi.org/10.1002/smll.201805510
• Gudapati, H.; Dey, M. and Ozbolat, I. A comprehensive review on droplet-based bioprinting: Past, present and future. Biomaterials. 2016, 102:20-42; https://doi.org/10.1016/j.biomaterials.2016.06.012
• Holle, A.W.; Young, J.L. and Spatz, J.P. In vitro cancer cell-ECM interactions inform in vivo cancer treatment. Advanced Drug Delivery Reviews. 2016, 97:270-279; https://doi.org/10.1016/j.addr.2015.10.007
• Nguyen, E.H.; Daly, W.T.; Le, N.N.T.; Farnoodian, M.; Belair, D.G.; Schwartz, M.P.; Lebakken, C.S.; Ananiev, G.E.; Saghiri, M.A.; Knudsen, T.B.; Sheibani, N. and Murphy W.L. Versatile synthetic alternatives to Matrigel for vascular toxicity screening and stem cell expansion. Nature Biomedical Engineering. 2017, 1:0096; https://doi.org/10.1038/s41551-017-0096
• Antoni. D.; Burckel, H.; Josset, E. and Noel, G. Three-Dimensional Cell Culture: A Breakthrough in Vivo. International Journal of Molecular Sciences. 2015, 16(3):5517-5527; https://doi.org/10.3390/ijms16035517
• Langhans, S.A. Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Frontiers in Pharmacology. 2018, 9:6; https://doi.org/10.3389/fphar.2018.00006